David A. X. Nayagam

David A. X. Nayagam

Auto-generated profile, based on publicly available information

David A. X. Nayagam

Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LALauren N. Ayton
Lauren N. Ayton
PBPeter J. Blamey
Peter J. Blamey
RGRobyn Guymer
Robyn Guymer
CLChi Luu
Chi Luu
DNDavid A. X. Nayagam
David A. X. Nayagam
FCfor the Bionic Vision Australia Research Consortium
for the Bionic Vision Australia Research Consortium
Retinal visual prostheses (“bionic eyes”) have the potential to restore vision to blind or profoundly vision-impaired patients. The medical bionic technology used to design, manufacture and implant such prostheses is still in its relative infancy, with various technologies and surgical approaches being evaluated. We hypothesised that a suprachoroidal implant location (between the sclera and choroid of the eye) would provide significant surgical and safety benefits for patients, allowing them to maintain preoperative residual vision as well as gaining prosthetic vision input from the device. This report details the first-in-human Phase 1 trial to investigate the use of retinal implants in the suprachoroidal space in three human subjects with end-stage retinitis pigmentosa. The success of the suprachoroidal surgical approach and its associated safety benefits, coupled with twelve-month post-operative efficacy data, holds promise for the field of vision restoration. Clinicaltrials.gov NCT01603576

1 October 2013 in Trends in Biotechnology
Verified
Journal Article
Closed access
RSRobert K. Shepherd
Robert K. Shepherd
MSMohit Naresh Shivdasani
Mohit Naresh Shivdasani
DNDavid A.X. Nayagam
David A.X. Nayagam
CWChristopher E. Williams
Christopher E. Williams
PBPeter J. Blamey
Peter J. Blamey

4 May 2015 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
NANicholas V. Apollo
Nicholas V. Apollo
MMMatias I. Maturana
Matias I. Maturana
WTWei Tong
Wei Tong
DNDavid A. X. Nayagam
David A. X. Nayagam
MSMohit Naresh Shivdasani
Mohit Naresh Shivdasani
DGDavid J. Garrett
David J. Garrett

1 August 2012 in Biomaterials
Verified
Journal Article
Closed access
AHAlex E. Hadjinicolaou
Alex E. Hadjinicolaou
RLRonald T. Leung
Ronald T. Leung
DGDavid J. Garrett
David J. Garrett
KGKumaravelu Ganesan
Kumaravelu Ganesan
KFKate Fox
Kate Fox
BOBrendan J. O’bRien
Brendan J. O’bRien

19 June 2018 in Journal of Neural Engineering
Verified
Journal Article
Closed access
PDF file
RSRobert K Shepherd
Robert K Shepherd
JVJoel Villalobos
Joel Villalobos
OBOwen Burns
Owen Burns
DNDavid A X Nayagam
David A X Nayagam
Objective . Given the rapid expansion of the field of neural stimulation and the rigorous regulatory approval requirements required before these devices can be applied clinically, it is important that there is clarity around conducting preclinical safety and efficacy studies required for the development of this technology. Approach . The present review examines basic design principles associated with the development of a safe neural stimulator and describes the suite of preclinical safety studies that need to be considered when taking a device to clinical trial. Main results . Neural stimulators are active implantable devices that provide therapeutic intervention, sensory feedback or improved motor control via electrical stimulation of neural or neuro-muscular tissue in response to trauma or disease. Because of their complexity, regulatory bodies classify these devices in the highest risk category (Class III), and they are therefore required to go through a rigorous regulatory approval process before progressing to market. The successful development of these devices is achieved through close collaboration across disciplines including engineers, scientists and a surgical/clinical team, and the adherence to clear design principles. Preclinical studies form one of several key components in the development pathway from concept to product release of neural stimulators. Importantly, these studies provide iterative feedback in order to optimise the final design of the device. Key components of any preclinical evaluation include: in vitro studies that are focussed on device reliability and include accelerated testing under highly controlled environments; in vivo studies using animal models of the disease or injury in order to assess efficacy and, given an appropriate animal model, the safety of the technology under both passive and electrically active conditions; and human cadaver and ex vivo studies designed to ensure the device’s form factor conforms to human anatomy, to optimise the surgical approach and to develop any specialist surgical tooling required. Significance . The pipeline from concept to commercialisation of these devices is long and expensive; careful attention to both device design and its preclinical evaluation will have significant impact on the duration and cost associated with taking a device through to commercialisation. Carefully controlled in vitro and in vivo studies together with ex vivo and human cadaver trials are key components of a thorough preclinical evaluation of any new neural stimulator.

1 August 2005 in Journal of Neurophysiology
Verified
Journal Article
Closed access
PDF file
DNDavid A. X. Nayagam
David A. X. Nayagam
JCJanine C. Clarey
Janine C. Clarey
APAntonio G. Paolini
Antonio G. Paolini
The function of the ventral nucleus of the lateral lemniscus (VNLL), a secondary processing site within the auditory brain stem, is unclear. It is known to be a major source of inhibition to the inferior colliculus (IC). It is also thought to play a role in coding the temporal aspects of sound, such as onsets and the periodic components of complex stimuli. In vivo intracellular recordings from VNLL neurons ( n = 56) in urethane anesthetized rats revealed the presence of large-amplitude, short-duration, onset inhibition in a subset of neurons (14.3%). This inhibition occurred before the first action potential (AP) elicited by noise or tone bursts, was broadly tuned to tonal frequency and was shown to delay the first AP. Our data suggest it is a result of an intrinsic circuit activated by the octopus cell pathway originating in the contralateral cochlear nucleus; this pathway is known to convey exquisitely timed and broadly tuned onset information. This powerful inhibition within the VNLL appears to control the timing of this structure's inhibitory output to higher centers, which has important auditory processing outcomes. The circuit also provides a pathway for fast, broadly tuned, onset inhibition to the IC.